Jeremy Grantham's ABT Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 8.48 M shares of Abbott Laboratories (ABT) worth $1.06 B, representing 2.72% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Jeremy Grantham has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2015, adding 1.62 M shares. Largest reduction occurred in Q2 2014, reducing 4.4 M shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +306,069 | Add 3.74% | 8.48 M | $125.29 |
| Q3 2025 | +361,946 | Add 4.63% | 8.18 M | $133.94 |
| Q2 2025 | -293,045 | Reduce 3.61% | 7.81 M | $136.01 |
| Q1 2025 | +210,644 | Add 2.67% | 8.11 M | $132.65 |
| Q4 2024 | +787,251 | Add 11.07% | 7.9 M | $113.11 |
| Q3 2024 | +1.32 M | Add 22.75% | 7.11 M | $114.01 |
| Q2 2024 | +384,152 | Add 7.10% | 5.79 M | $103.91 |
| Q1 2024 | +1.03 M | Add 23.60% | 5.41 M | $113.66 |
| Q4 2023 | +710,501 | Add 19.39% | 4.38 M | $110.07 |
| Q3 2023 | +801,191 | Add 27.98% | 3.66 M | $96.85 |
| Q2 2023 | +1.22 M | Add 73.71% | 2.86 M | $109.02 |
| Q1 2023 | +13,059 | Add 0.80% | 1.65 M | $101.26 |
| Q4 2022 | -15,800 | Reduce 0.96% | 1.64 M | $109.79 |
| Q3 2022 | +43,860 | Add 2.73% | 1.65 M | $96.76 |
| Q2 2022 | -40,129 | Reduce 2.44% | 1.61 M | $108.65 |
| Q1 2022 | -41,277 | Reduce 2.44% | 1.65 M | $118.36 |
| Q4 2021 | -67,118 | Reduce 3.82% | 1.69 M | $140.74 |
| Q3 2021 | +24,686 | Add 1.43% | 1.76 M | $118.13 |
| Q2 2021 | +6,799 | Add 0.39% | 1.73 M | $115.93 |
| Q1 2021 | -53,582 | Reduce 3.01% | 1.72 M | $119.84 |
| Q4 2020 | -132,242 | Reduce 6.92% | 1.78 M | $109.49 |
| Q3 2020 | +710,770 | Add 59.26% | 1.91 M | $108.83 |
| Q2 2020 | -252,951 | Reduce 17.42% | 1.2 M | $91.43 |
| Q1 2020 | -353,745 | Reduce 19.59% | 1.45 M | $78.91 |
| Q4 2019 | +5,195 | Add 0.29% | 1.81 M | $86.86 |
| Q3 2019 | +52,749 | Add 3.02% | 1.8 M | $83.67 |
| Q2 2019 | -89,609 | Reduce 4.88% | 1.75 M | $84.10 |
| Q1 2019 | -181,881 | Reduce 9.01% | 1.84 M | $79.94 |
| Q4 2018 | -255,139 | Reduce 11.22% | 2.02 M | $72.33 |
| Q3 2018 | -283,391 | Reduce 11.08% | 2.27 M | $73.36 |
| Q2 2018 | -826,002 | Reduce 24.41% | 2.56 M | $60.99 |
| Q1 2018 | -1.44 M | Reduce 29.79% | 3.38 M | $59.92 |
| Q4 2017 | -33,200 | Reduce 0.68% | 4.82 M | $57.07 |
| Q3 2017 | -398,392 | Reduce 7.59% | 4.85 M | $53.36 |
| Q2 2017 | +243,161 | Add 4.85% | 5.25 M | $48.61 |
| Q1 2017 | +523,854 | Add 11.68% | 5.01 M | $44.41 |
| Q4 2016 | -25,404 | Reduce 0.56% | 4.48 M | $38.41 |
| Q3 2016 | +165,114 | Add 3.80% | 4.51 M | $42.29 |
| Q2 2016 | +632,054 | Add 17.02% | 4.35 M | $39.31 |
| Q1 2016 | -1.94 M | Reduce 34.32% | 3.71 M | $41.83 |
| Q4 2015 | -815,905 | Reduce 12.61% | 5.65 M | $44.91 |
| Q3 2015 | -3.03 M | Reduce 31.90% | 6.47 M | $40.22 |
| Q2 2015 | -1.23 M | Reduce 11.45% | 9.5 M | $49.08 |
| Q1 2015 | +1.62 M | Add 17.76% | 10.73 M | $46.33 |
| Q4 2014 | -1.05 M | Reduce 10.29% | 9.11 M | $45.02 |
| Q3 2014 | -1.8 M | Reduce 15.06% | 10.16 M | $41.59 |
| Q2 2014 | -4.4 M | Reduce 26.92% | 11.96 M | $40.90 |
| Q1 2014 | +206,170 | Add 1.28% | 16.36 M | $38.51 |
| Q4 2013 | +124,422 | Add 0.78% | 16.15 M | $38.33 |
| Q3 2013 | -1.56 M | Reduce 8.85% | 16.03 M | $33.19 |
| Q2 2013 | +17.59 M | Add 0.00% | 17.59 M | $34.88 |
Jeremy Grantham's Abbott Laboratories Investment FAQs
Jeremy Grantham first purchased Abbott Laboratories (ABT) in Q2 2013, acquiring 17,586,829 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Abbott Laboratories (ABT) for 51 quarters since Q2 2013.
Jeremy Grantham's largest addition to Abbott Laboratories (ABT) was in Q2 2013, adding 17,586,829 shares worth $613.43 M.
According to the latest 13F filing for Q4 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 8,482,553 shares of Abbott Laboratories (ABT), valued at approximately $1.06 B.
As of the Q4 2025 filing, Abbott Laboratories (ABT) represents approximately 2.72% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Abbott Laboratories (ABT) was 17,586,829 shares, as reported at the end of Q2 2013.